89bio reports fourth quarter and full year 2023 financial results and provides corporate updates

– plan to initiate the phase 3 enlighten nash program for non-cirrhotic (f2-f3) and cirrhotic (f4) patients in the first and second quarters of 2024, respectively –

ETNB Ratings Summary

ETNB Quant Ranking